tetano
Editor, Senior Moderator
Cells
. 2021 Jun 8;10(6):1434.
doi: 10.3390/cells10061434.
SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2
Claudio Fenizia[SUP] 1 2 [/SUP], Silvia Galbiati[SUP] 3 [/SUP], Claudia Vanetti[SUP] 1 2 [/SUP], Riccardo Vago[SUP] 4 5 [/SUP], Mario Clerici[SUP] 1 6 [/SUP], Carlo Tacchetti[SUP] 5 7 [/SUP], Tiziana Daniele[SUP] 7 [/SUP]
Affiliations
Abstract
In late 2019, the betacoronavirus SARS-CoV-2 was identified as the viral agent responsible for the coronavirus disease 2019 (COVID-19) pandemic. Coronaviruses Spike proteins are responsible for their ability to interact with host membrane receptors and different proteins have been identified as SARS-CoV-2 interactors, among which Angiotensin-converting enzyme 2 (ACE2), and Basigin2/EMMPRIN/CD147 (CD147). CD147 plays an important role in human immunodeficiency virus type 1, hepatitis C virus, hepatitis B virus, Kaposi's sarcoma-associated herpesvirus, and severe acute respiratory syndrome coronavirus infections. In particular, SARS-CoV recognizes the CD147 receptor expressed on the surface of host cells by its nucleocapsid protein binding to cyclophilin A (CyPA), a ligand for CD147. However, the involvement of CD147 in SARS-CoV-2 infection is still debated. Interference with both the function (blocking antibody) and the expression (knock down) of CD147 showed that this receptor partakes in SARS-CoV-2 infection and provided additional clues on the underlying mechanism: CD147 binding to CyPA does not play a role; CD147 regulates ACE2 levels and both receptors are affected by virus infection. Altogether, these findings suggest that CD147 is involved in SARS-CoV-2 tropism and represents a possible therapeutic target to challenge COVID-19.
Keywords: ACE2; CD147; COVID-19; EMMPRIN; SARS-CoV-2; basigin; entry; infection.
. 2021 Jun 8;10(6):1434.
doi: 10.3390/cells10061434.
SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2
Claudio Fenizia[SUP] 1 2 [/SUP], Silvia Galbiati[SUP] 3 [/SUP], Claudia Vanetti[SUP] 1 2 [/SUP], Riccardo Vago[SUP] 4 5 [/SUP], Mario Clerici[SUP] 1 6 [/SUP], Carlo Tacchetti[SUP] 5 7 [/SUP], Tiziana Daniele[SUP] 7 [/SUP]
Affiliations
- PMID: 34201214
- DOI: 10.3390/cells10061434
Abstract
In late 2019, the betacoronavirus SARS-CoV-2 was identified as the viral agent responsible for the coronavirus disease 2019 (COVID-19) pandemic. Coronaviruses Spike proteins are responsible for their ability to interact with host membrane receptors and different proteins have been identified as SARS-CoV-2 interactors, among which Angiotensin-converting enzyme 2 (ACE2), and Basigin2/EMMPRIN/CD147 (CD147). CD147 plays an important role in human immunodeficiency virus type 1, hepatitis C virus, hepatitis B virus, Kaposi's sarcoma-associated herpesvirus, and severe acute respiratory syndrome coronavirus infections. In particular, SARS-CoV recognizes the CD147 receptor expressed on the surface of host cells by its nucleocapsid protein binding to cyclophilin A (CyPA), a ligand for CD147. However, the involvement of CD147 in SARS-CoV-2 infection is still debated. Interference with both the function (blocking antibody) and the expression (knock down) of CD147 showed that this receptor partakes in SARS-CoV-2 infection and provided additional clues on the underlying mechanism: CD147 binding to CyPA does not play a role; CD147 regulates ACE2 levels and both receptors are affected by virus infection. Altogether, these findings suggest that CD147 is involved in SARS-CoV-2 tropism and represents a possible therapeutic target to challenge COVID-19.
Keywords: ACE2; CD147; COVID-19; EMMPRIN; SARS-CoV-2; basigin; entry; infection.